stockrowNovo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +4.47%
- EPS
- −18.7%
- Free cash flow
- +71.6%
- Total debt
- +44.4%
Quarter to June 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) Operating cash flow
Novo Nordisk A/S's operating cash flow for fiscal 2025 was $18.0B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $20.4B. Over the past ten years it has ranged from $5.7B (fiscal 2015) to $18.0B (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 8 consecutive fiscal years. Novo Nordisk A/S ranks 4th of 21 Drug Manufacturers General companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $18.0B | 2.80% |
| FY2024 | $17.5B | 10.92% |
| FY2023 | $15.8B | 41.57% |
| FY2022 | $11.2B | 27.65% |
| FY2021 | $8.8B | 9.95% |
| FY2020 | $8.0B | 13.49% |
| FY2019 | $7.0B | 2.80% |
| FY2018 | $6.8B | 9.09% |
| FY2017 | $6.3B | (12.90%) |
| FY2016 | $7.2B | 26.02% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $8.6B | 127.09% |
| Mar 2026 | $3.8B | 557.29% |
| Dec 2025 | $573.8M | (92.36%) |
| Sep 2025 | $7.5B | 16.07% |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SNY Sanofi compare | $23.8B |
| NVO Novo Nordisk A/S | $20.4B |
| NVS Novartis AG compare | $17.3B |
| GILD Gilead Sciences, Inc. compare | $14.5B |
| PFE Pfizer Inc. compare | $14.2B |
| AZN AstraZeneca PLC compare | $13.2B |
| AMGN Amgen Inc. compare | $12.0B |
| GSK GSK PLC Sponsored ADR compare | $11.8B |
| BMY Bristol Myers Squibb Company compare | $10.7B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on NVO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement